Garland Jonathan Todd has filed 14 insider transactions across 1 company since March 2023.
Most recent transaction: a option exercise of 1951 shares of Cytek Biosciences, Inc. ($CTKB) on August 18, 2023.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Common Stock | 1951 | $0.00 | 7,838.0000 | 138,562,111 | 33.14% | 0.00% |
| Aug. 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | F | Common Stock | 760 | $8.46 | 7,078.0000 | 138,562,111 | 9.70% | 0.00% |
| Aug. 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Common Stock | 2761 | $0.00 | 9,839.0000 | 138,562,111 | 39.01% | 0.00% |
| Aug. 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | F | Common Stock | 1076 | $8.46 | 8,763.0000 | 138,562,111 | 10.94% | 0.00% |
| Aug. 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Restricted Stock Units | 1951 | $0.00 | 21,462.0000 | 138,562,111 | 8.33% | 0.00% |
| Aug. 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Restricted Stock Units | 2761 | $0.00 | 39,579.0000 | 138,562,111 | 6.52% | 0.00% |
| May 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Common Stock | 7804 | $0.00 | 7,804.0000 | 138,562,111 | 9999.99% | 0.01% |
| May 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | F | Common Stock | 3040 | $6.69 | 4,764.0000 | 138,562,111 | 38.95% | 0.00% |
| May 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Common Stock | 1840 | $0.00 | 6,604.0000 | 138,562,111 | 38.62% | 0.00% |
| May 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | F | Common Stock | 717 | $6.69 | 5,887.0000 | 138,562,111 | 10.86% | 0.00% |
| May 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Restricted Stock Units | 7804 | $0.00 | 23,413.0000 | 138,562,111 | 25.00% | 0.01% |
| May 18, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | M | Restricted Stock Units | 1840 | $0.00 | 42,340.0000 | 138,562,111 | 4.16% | 0.00% |
| March 3, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | A | Employee Stock Option (right to buy) | 66773 | $0.00 | 66,773.0000 | 138,562,111 | 9999.99% | 0.05% |
| March 3, 2023 | Cytek Biosciences, Inc. | $CTKB | Garland Jonathan Todd | Chief Commercial Officer | A | Restricted Stock Units | 44180 | $0.00 | 44,180.0000 | 138,562,111 | 9999.99% | 0.03% |